Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-ascending-dose safety and pharmacokinetics study of CG400549 in healthy volunteers
NL-OMON34490Active, not recruiting
- Sponsor
- Crystal Genomics
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of nilofabicin in Staphylococcus aureus infection (2 arms), sponsored by Crystal Genomics. Primary endpoints: Pharmacokinetics of CG400549 and Safety and tolerability. Started May 2010; status: active, not recruiting.
02
Drugs
nilofabicin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NL-OMON34490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34490.